ANI PHARMACEUTICALS INC
For the period ended Jun 30, 2025. Filed Aug 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 8, 2025
ANIP$71.25+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities | ||
| Net income | $24,230 | $15,920 |
| Adjustments to reconcile net income to net cash and cash equivalents provided by operating activities: | ||
| Stock-based compensation | 18,470 | 14,798 |
| Deferred taxes | (6,919) | 1,205 |
| Depreciation and amortization | 46,172 | 29,383 |
| Unrealized loss (gain) on investment in equity securities | 589 | (6,943) |
| Non-cash operating lease expense | 846 | 750 |
| Non-cash interest | 665 | 198 |
| Contingent consideration fair value adjustment | (10,815) | 449 |
| Gain on sale of building | — | (5,347) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (3,709) | (4,012) |
| Inventories | (1,533) | (14,252) |
| Prepaid expenses and other assets | 5,890 | 1,777 |
| Accounts payable | 8,625 | 10,379 |
| Accrued royalties | 13,404 | 4,081 |
| Income taxes | (3,455) | (11,031) |
| Accrued government rebates | 14,152 | 156 |
| Returned goods reserve | 9,409 | 4,219 |
| Accrued expenses, accrued compensation, and other | (5,218) | (6,047) |
| Net Cash and Cash Equivalents Provided by Operating Activities | 110,803 | 35,683 |
| Cash Flows From Investing Activities | ||
| Acquisition of product rights, intangible assets, and other related assets | (20,267) | — |
| Acquisition of property and equipment, net | (6,488) | (9,030) |
| Proceeds from the sale of building | — | 13,514 |
| Net Cash and Cash Equivalents (Used in) Provided by Investing Activities | (26,755) | 4,484 |
| Cash Flows From Financing Activities | ||
| Principal payments on borrowings | (4,062) | (1,500) |
| Series A convertible preferred stock dividends paid | (813) | (813) |
| Proceeds from stock option exercises and ESPP purchases | 3,776 | 3,596 |
| Treasury stock purchases for restricted stock vests | (10,554) | (9,961) |
| Payments on contingent consideration | — | (12,500) |
| Net Cash and Cash Equivalents Used in Financing Activities | (11,653) | (21,178) |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | 544 | — |
| Net Change in Cash, Cash Equivalents, and Restricted Cash | 72,939 | 18,989 |
| Cash, cash equivalents, and restricted cash, beginning of period | 144,894 | 221,121 |
| Cash, cash equivalents, and restricted cash end of period | $217,833 | $240,110 |
| Supplemental disclosure for cash flow information: | ||
| Cash paid for interest, net of amounts capitalized | $13,861 | $16,155 |
| Cash paid for income taxes | $16,473 | $17,204 |
| Supplemental non-cash investing and financing activities: | ||
| Property and equipment purchased and included in accounts payable | $288 | $1,618 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.